Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Molecular Cancer Therapeutics
Jeremy KarlinKristoffer Valerie

Abstract

Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that current inhibitors have limited central nervous system (CNS) bioavailability; thus, the goal was to identify ATM inhibitors (ATMi) with improved CNS penetration. Drug screens and refinement of lead compounds identified AZ31 and AZ32. The compounds were then tested in vivo for efficacy and impact on tumor and healthy brain. Both AZ31 and AZ32 blocked the DNA damage response and radiosensitized GBM cells in vitro AZ32, with enhanced blood-brain barrier (BBB) penetration, was highly efficient in vivo as radiosensitizer in syngeneic and human, orthotopic mouse glioma model compared with AZ31. Furthermore, human glioma cell lines expressing mutant p53 or having checkpoint-defective mutations were particularly sensitive to ATMi radiosensitization. The mechanism for this p53 effect involves a propensity to undergo mitotic catastrophe relative to cells with wild-type p53. In vivo, apoptosis was >6-fold higher in tumor relative to healthy brain after exposure to AZ32 and low-dose radiation. ...Continue Reading

References

Feb 7, 1998·Genes & Development·J D SilicianoM B Kastan
Sep 7, 2001·Genes & Development·R T Abraham
Jan 26, 2002·Molecular and Cellular Biology·Bo XuMichael B Kastan
Mar 19, 2002·EMBO Reports·Fumiko Toyoshima-MorimotoEisuke Nishida
Aug 6, 2002·Nature Medicine·Michelle L MonjeTheo D Palmer
Jan 31, 2003·Nature·Christopher J Bakkenist, Michael B Kastan
Aug 30, 2003·Oncogene·Kristoffer Valerie, Lawrence F Povirk
Nov 19, 2004·Nature·Michael B Kastan, Jiri Bartek
Jan 28, 2005·Journal of Neuro-oncology·Joachim P Steinbach, Michael Weller
Jul 11, 2008·Nature·Libor MacůrekRené H Medema
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 25, 2008·Nature Reviews. Molecular Cell Biology·Martin F Lavin
Feb 20, 2009·Proceedings of the National Academy of Sciences of the United States of America·Surojit SurNickolas Papadopoulos
Sep 10, 2009·Cancer Science·Hiroko Ohgaki, Paul Kleihues
Dec 9, 2010·Science Signaling·Ariel BensimonYosef Shiloh
Nov 15, 2011·Trends in Biochemical Sciences·Scott Ditch, Tanya T Paull
Oct 12, 2012·Journal of Visualized Experiments : JoVE·Jason M BecktaKristoffer Valerie
Jan 16, 2013·Oncogene·J G Jackson, G Lozano
Mar 15, 2013·Nature Reviews. Molecular Cell Biology·Yosef Shiloh, Yael Ziv
Apr 27, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura Biddlestone-ThorpeKristoffer Valerie
Dec 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carlos Rodrigo Gil del AlcazarSandeep Burma
Sep 11, 2014·Molecular Oncology·Ross CarruthersAnthony J Chalmers
Dec 30, 2016·Nature Reviews. Clinical Oncology·Guido ReifenbergerMichael Weller

❮ Previous
Next ❯

Citations

Oct 9, 2019·Current Opinion in Neurology·Jason M BecktaAnthony J Chalmers
Jun 9, 2020·Expert Reviews in Molecular Medicine·Hannah L SmithNicola J Curtin
Jun 17, 2020·Investigative Ophthalmology & Visual Science·Oleg AlekseevJane Azizkhan-Clifford
Sep 15, 2020·Journal of Huntington's Disease·Caroline L BennDavid S Reynolds
May 2, 2020·Signal Transduction and Targeted Therapy·Rui-Xue Huang, Ping-Kun Zhou
Jul 16, 2020·International Journal of Molecular Sciences·Alessandra FerriDaniela Barilà
Jan 30, 2021·The FEBS Journal·Benjamin Edginton-White, Constanze Bonifer
Nov 3, 2020·Journal of Medicinal Chemistry·Samuel H MyersAndrea Cavalli
Feb 7, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jasmine AllenKristoffer Valerie
Mar 20, 2021·Neuro-oncology Advances·Nazanin K MajdJohn F de Groot
Mar 31, 2021·Journal of Medicinal Chemistry·Amanda Van de PoëlCelia Dominguez
Jun 8, 2021·Frontiers in Oncology·Kun LiuZhi Shi
Jun 26, 2021·Pharmacology & Therapeutics·Fengchao LangChunzhang Yang
Sep 25, 2021·Nature Structural & Molecular Biology·K StakyteK P Hopfner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.